<DOC>
	<DOCNO>NCT01551147</DOCNO>
	<brief_summary>The primary objective - determine effect ONO-6950 200 mg QD versus placebo administer 8 day early asthmatic response ( EAR ) late asthmatic response ( LAR ) induce inhaled allergen - determine safety tolerability ONO-6950 200 mg QD administer 8 day patient asthma The secondary objective : - compare effect ONO-6950 versus montelukast % decrease FEV1 follow allergen exposure , - determine effect ONO-6950 versus placebo montelukast allergen-induced airway hyperresponsiveness ( AHR ) measure methacholine challenge</brief_summary>
	<brief_title>A Placebo Active Controlled Study ONO-6950 Following Allergen Challenge Patients With Asthma</brief_title>
	<detailed_description>The study examine ONO-6950 could alleviate EAR LAR cause allergen challenge subject asthma . Patients required EAR LAR standardize allergen challenge screen . Eligible patient complete randomize , double-blind , three-way crossover study . During three evaluation period , patient administer either 200 mg ONO-6950 , 10 mg Montelukast , placebo 8 day . Each evaluation period occur 8 day include various assessment follow allergen challenge methacholine challenge . The study require overnight stay clinical research center .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patients gender , 18 60 year age , bronchial asthma symptom least 6 month Patients FEV1 ≥ 70 % predict withhold shortacting β agonist least 8 hour prior test Screening allergen challenge demonstrate patient experience early late asthmatic response Sensitivity methacholine result ≥ 20 % fall FEV1 ( PC20 methacholine ) Nonsmokers free usage nicotinecontaining product least year prior screen Previous history lifethreatening asthma , respiratory tract infection and/or exacerbation asthma within 6 week prior first screen visit Past present disorder diseases include , limited , cardiovascular , malignancy , hepatic , renal , hematological , neurological , psychiatric , endocrine , pulmonary asthma Significant safety laboratory , ECG , vital sign abnormality would place patient undue disk study procedure History clinically significant multiple drug food allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>ONO-6950</keyword>
	<keyword>asthma adult patient</keyword>
</DOC>